Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | L. Cripe, W. McGuire, M. Wertheim, P. Eisenberg, W. Stadler, R. Paquette, T. Logan, T. Zimmerman, D. Matei, U. Matulonis | ||||||||||||
Title | Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM) | ||||||||||||
|
|||||||||||||
URL | http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/3591 | ||||||||||||
Abstract Text | J Clin Oncol, 25:18s, 2007 (suppl; abstr 3591) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XL999 | XL-999|XL 999 | FGFR1 Inhibitor 28 FGFR3 Inhibitor 19 FLT3 Inhibitor 66 KIT Inhibitor 57 PDGFR-beta Inhibitor 14 RET Inhibitor 52 SRC Inhibitor 31 VEGFR2 Inhibitor 37 | XL999 inhibits multiple tyrosine kinases including VEGFR2/KDR, FGFR1/3, PDGFR-beta, FLT3, RET, KIT, and SRC, which can result in anti-tumor activity (J Clin Oncol, 25:18s, 2007 (suppl;abstr 3591), PMID: 19581523). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|